

Monoclonal Antibody to Human IFN- γ

Cat. No. AXIFN02RAB

Recombinant Antibody

STORE AT -20 °C

Validated Assay Configuration – The following configuration represents the AssayProven™ recommended reagent combination for the validated application listed below.

VALIDATED APPLICATION	CLIA
CAPTURE REAGENT	AXIFN01MAB
DETECTION REAGENT	AXIFN02RAB
PERFORMANCE EVALUATION MATERIAL	Clinical samples

Product Characteristics

SPECIES OF ORIGIN	Mouse
PRODUCTION SYSTEM	HEK293 cells
RECOMBINANT	Yes
ISOTYPE	IgG
MOLECULAR WEIGHT	150 kDa (50 kDa heavy chain, 25 kDa light chain)
FULL-LENGTH PROTEIN	Yes
APPEARANCE	Clear liquid
FORMAT	Liquid
CONCENTRATION	≥1 mg/mL
METHOD TO DETERMINE CONCENTRATION	OD280
LYOPHILIZED	No
RECONSTITUTION METHOD	Not applicable
SONICATION REQUIRED PRIOR TO USE	No

Biological Characteristics

IMMUNOGEN	Recombinant human IFN-γ
IMMUNOGEN SEQUENCE	P01579 (UniProt ID)
AMINO ACID SEQUENCE	Not characterized
TAG PROTEIN	Not characterized
EPITOPE	Not characterized
CROSS-REACTIVITY	Not characterized
IMMUNOREACTIVITY	Not characterized

Quality Attributes

PURITY	≥90%
METHOD TO DETERMINE PURITY	SDS-PAGE
PURIFICATION METHOD	Affinity chromatography
MAXIMUM BIOBURDEN	Not characterized

Binding Characteristics

ASSOCIATION RATE CONSTANT (K_a)	Not characterized
DISSOCIATION RATE CONSTANT (K_d)	Not characterized
EQUILIBRIUM DISSOCIATION CONSTANT (K_D)	Not characterized
BINDING DETERMINATION METHOD	Not characterized

Formulation

BUFFER / PH	PBS, pH 7.3
PRESERVATIVE	0.09% sodium azide

Storage & Stability

STORAGE TEMPERATURE	-20 °C
SHELF LIFE	12 months
STABILITY AT 2–8 °C	12 months
STABILITY AT -20 °C	12 months
STABILITY AT -40 °C	Not characterized
STABILITY AT -80 °C	Not characterized

Other Technical characteristics

ISOELECTRIC POINT (pI)	7.1
INACTIVATION METHOD	Not applicable

Notes & Safety Information

SAFETY INFORMATION	Refer to the appropriate Safety Data Sheet (SDS) for additional information.
NOTES	This reagent has been manufactured under ISO 13485 quality management system and is suitable for research or further manufacturing use only. Centrifuge before opening to ensure complete recovery of vial contents.

Performance Validation Report

The following pages contain the applicable AssayProven™ Performance Validation Report.


AssayProven™ Recommended Human Interferon-γ Antibody Pair

Recommended Pair Summary

Multiple antibody combinations were screened under standardized assay conditions to identify the optimal antibody pair for chemiluminescent immunoassay development. The recommended AssayProven™ IFN-γ antibody pair demonstrated the best overall analytical performance, including excellent analytical sensitivity, strong correlation with the comparator assay, and high clinical agreement, supporting its suitability for chemiluminescent immunoassay development.

Category	Target	Format	Item Type	Cat. #	Description	Function
Infectious Disease	Human IFN-γ	CLIA	Antibody	AXIFN01MAB	mAb to Human IFN-γ	Capture
			Antibody	AXIFN02RAB	mAb to Human IFN-γ	Detector

Method: 1-step sandwich assay



Magnetic bead coated with Meridian capture antibody

Human IFN-γ analyte

Meridian detection antibody

Figure 1. Schematic diagram of a 1-step sandwich chemiluminescent immunoassay using AssayProven™ pairs.

Correlation Performance




Figure 2. Correlation between the Meridian IFN-γ CLIA assay and the SD Biosensor TB-Feron ELISA assay using clinical samples (n = 49).

Analytical & Clinical Performance

SD Biosensor TB-Feron ELISA	Meridian IFN-γ CLIA
Overall Agreement	99% (409/414)
PPA (Positive Percent Agreement)	99% (198/200)
NPA (Negative Percent Agreement)	99% (197/200)

Table 1. Clinical agreement between the Meridian IFN-γ CLIA assay and the SD Biosensor TB-Feron ELISA assay.

Type	Result
LoB	0.02 IU/mL
LoD	0.04 IU/mL
LoQ	0.07 IU/mL

Table 2. Analytical sensitivity of the Meridian IFN-γ CLIA assay.